Genetics and present therapy options in Parkinson's disease: A review;A parkinson-kór genetikája és aktuális terápiás lehetocombining double acute accentségei

Ideggyogyaszati Szemle

Volumn 62, Issue 5-6, 2009, Pages 155-163

  Bereznai, Benjamin ^a   Molnár, Mária Judit ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Deep brain stimulation; Gen test; Genetics; Multidisciplinary therapy; Parkinson disease; Slow release dopamin agonist

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PARKIN; ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; LRRK2 PROTEIN, HUMAN; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PTEN INDUCED PUTATIVE KINASE; PTEN-INDUCED PUTATIVE KINASE; SIGNAL PEPTIDE; UBIQUITIN PROTEIN LIGASE;

GENETIC ASSOCIATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; BRAIN DEPTH STIMULATION; GENE THERAPY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; MUSIC THERAPY; PHYSIOTHERAPY; PSYCHOTHERAPY; RELAXATION TRAINING;

ALPHA-SYNUCLEIN; ANTIPARKINSON AGENTS; COMBINED MODALITY THERAPY; DANCE THERAPY; DEEP BRAIN STIMULATION; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSIC THERAPY; ONCOGENE PROTEINS; PARKINSON DISEASE; PHYSICAL THERAPY MODALITIES; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PSYCHOTHERAPY; RELAXATION THERAPY; UBIQUITIN-PROTEIN LIGASES;

EID: 67651064960     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution. Multiple clues to a complex disorder. Neurology 2007 Aug. 29.
2. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51(3):296-301.
3. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44(4):595-600. (Pubitemid 39531224)
4. Zimprich A, Müller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004;74(1):11-9. (Pubitemid 38085234)
5. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V; Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005;365(9457):412-5.
6. Lesage S, Dürr A, Brice A. LRRK2 is a major gene in North African parkinsonism. Med Sci (Paris) 2006;22(5):470-1.
7. Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 2007;69(16):1595-602.
8. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365(9457):415-6. (Pubitemid 40179229)
9. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005;6(4):171-7. (Pubitemid 41720888)
10. Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006;67(10):1786-91. Epub 2006 Oct 18. (Pubitemid 44900754)
11. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354(4):424-5. (Pubitemid 43145083)
12. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62(9):1619-22. (Pubitemid 38608210)
13. Abbas N, Lücking CB, Ricard S, Dürr A, Bonifati V, De Michele G, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 1999;8(4):567-74.
14. Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denèfle P, Wood NW, Agid Y, Brice A; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342(21):1560-7.
15. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392(6676):605-8.
16. Lücking CB, Abbas N, Dürr A, Bonifati V, Bonnet AM, de Broucker T, et al. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet 1998;352(9137):1355-6. (Pubitemid 28510921)
17. Matsumine H, Yamamura Y, Hattori N, Kobayashi T, Kitada T, Yoritaka A, et al. A microdeletion of D6S305 in a family of autosomal recessive juvenile parkinsonism (PARK2). Genomics 1998;49(1):143-6. (Pubitemid 28194448)
18. Wang M, Hattori N, Matsumine H, Kobayashi T, Yoshino H, Morioka A, et al. Polymorphism in the parkin gene in sporadic Parkinson's disease. Ann Neurol 1999;45(5):655-8. (Pubitemid 29217595)
19. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000;97(24):13354-9.
20. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body forma tion in Parkinson disease. Nat Med 2001;7(10):1144-50. (Pubitemid 33010024)
21. Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y, et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005;25(8):2002-9. (Pubitemid 40289405)
22. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304(5674):1158-60. (Pubitemid 38661852)
23. Valente EM, Brancati F, Ferraris A, Graham EA, Davis MB, Breteler MM, Gasser T, Bonifati V, Bentivoglio AR, De Michele G, Dürr A, Cortelli P, Wassilowsky D, Harhangi BS, Rawal N, Caputo V, Filla A, Meco G, Oostra BA, Brice A, Albanese A, Dallapiccola B, Wood NW; European Consortium on Genetic Susceptibility in Parkinson's Disease. PARK6-linked parkinsonism occurs in several European families. Ann Neurol 2002;51(1):14-8.
24. Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004;61(12):1898-904. (Pubitemid 39612950)
25. Bonifati V, Rohé CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P, De Gaetano A, Horstink MW, Maat-Kievit JA, Sampaio C, Antonini A, Stocchi F, Montagna P, Toni V, Guidi M, Dalla Libera A, Tinazzi M, De Pandis F, Fabbrini G, Goldwurm S, de Klein A, Barbosa E, Lopiano L, Martignoni E, Lamberti P, Vanacore N, Meco G, Oostra BA; Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005;65(1):87-95.
26. Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 2004;56(3):424-7.
27. Abou-Sleiman PM, Muqit MM, McDonald NQ, Yang YX, Gandhi S, Healy DG, et al. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 2006;60(4):414-9.
28. Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA. 2004;101(24):9103-8. Epub 2004 Jun 4. (Pubitemid 38781618)
29. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276(5321):2045-7. (Pubitemid 27443610)
30. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4(11):1318-20.
31. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-40.
32. Volles MJ, Lansbury PT Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002;41(14):4595-602. (Pubitemid 34275660)
33. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294(5545):1346-9. (Pubitemid 33063102)
34. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, Chartier-Harlin MC, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert JC, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan EK, Van Broeckhoven C; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006;296(6):661-70.
35. Ibáñez P, Lehmann E, Pollak P, Durif F, Tranchant C, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. Absence of NR4A2 exon 1 mutations in 108 families with autosomal dominant Parkinson disease. Neurology 2004;62(11):2133-4.
36. Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, et al. Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008;70(1):43-9.
37. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007;6(7):652-62. (Pubitemid 46921058)
38. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000;284(15):1931-8.
39. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342(20):1484-91. (Pubitemid 30318272)
40. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989;46(10):1052-60.
41. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937-43.
42. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999;56(5):529-35. (Pubitemid 29218147)
43. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54(1):93-101. (Pubitemid 36764985)
44. Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 2007;29(12):2654-66.
45. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL; EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68(14):1108-15.
46. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6(6):513-20. (Pubitemid 46734759)
47. Pinter MM, Alesch F, Murg M, Seiwald M, Helscher RJ, Binder H. Deep brain stimulation of the subthalamic nucleus for control of extrapyramidal features in advanced idiopathic parkinson's disease: one year follow-up. J Neural Transm 1999;106(7-8):693-709. (Pubitemid 29401357)
48. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339(16):1105-11. (Pubitemid 28465758)
49. Deep-brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345(13):956-63.
50. Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001;56 (4):548-51. (Pubitemid 32172887)
51. Krack P, Pollak P, Limousin P, Benazzouz A, Benabid AL. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease. Lancet 1997;350(9092):1675. (Pubitemid 28036830)
52. Rodriguez MC, Guridi OJ, Alvarez L, Mewes K, Macias R, Vitek J, et al. The subthalamic nucleus and tremor in Parkinson's disease. Mov Disord 1998;13(Suppl3):111-8. (Pubitemid 28517770)
53. Krack P, Benazzouz A, Pollak P, Limousin P, Piallat B, Hoffmann D, et al. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov Disord 1998;13(6):907-14. (Pubitemid 28517667)
54. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Prolong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 2002;58(3):396-401. (Pubitemid 34150913)
55. Hendrich A, Holig G. Sport und Morbus Parkinson - Grenzen und Möglichkeiten. In: Przuntek H, Müller Th: Adjuvante nicht-medikamentöse Therapieansätze bei Morbus Parkinson Darmstadt, 2000, Steinkopff Verlag, 57-64.
56. Götz W. History of treatment of Parkinson disease. Pharm Unserer Zeit 2006;35(3):190-7.
57. Reinnardy L. Heileurhythmie bei Morbus Parkinson. In: Przuntek H, Müller TH. Adjuvante nicht-medikamentöse Therapieansätze bei Morbus Parkinson Darmstadt, 2000, Steinkopff Verlag, 112-15.
58. Dill-Schmölders C. Rhythmus als spezifischer Wirkfaktor in der Behandlung von Parkinson-PatientInnen. In: Jochims S. Musiktherapie in der Neurorehabilitation. München: Hippocampus Verlag; 162-80.
59. Kohl F. Progressive muscle relaxation according to E. Jacobson. A modern relaxation technique. Med Monatsschr Pharm 2002;25(3):77-87.
60. Macht M, Ellgring H. Psychologische Interventionen bei der Parkinson-Erkrankung. 2003, Stuttgart: Kohlhammer.
61. Gonzalez-Alegre P. Therapeutic RNA interference for neurodegenerative diseases: from promise to progress. Pharmacol Ther 2007;114:34-55. (Pubitemid 46509658)
62. Mochizuki H, Yamada M, Mizuno Y. Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease. Parkinsonism Relat Disord 2006;12:S107-S109. (Pubitemid 44466465)
63. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005;46:857-68. (Pubitemid 40805347)
64. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-105. (Pubitemid 46935946)